Advancements and future directions in cardiac biomarker detection using lateral flow assays

Lateral flow assays (LFAs) have emerged as one of the most prominent paper-based biosensor platforms for rapidly detecting and quantifying analytes. Their selectivity, cost-effectiveness, efficiency, and simplicity make them ideal candidates for point-of-care (POC) applications, particularly when time-sensitive decisions are needed, such as cardiovascular events. The profound impact of cardiovascular diseases (CVDs), characterized by their high morbidity, mortality, and rehospitalization rates, necessitates an optimized approach for the early detection of cardiac muscle damage. This comprehensive review aims to consolidate the existing scientific literature on LFAs that specifically target cardiovascular biomarkers, including myoglobin and cardiac troponin I, over the past decade. By examining the advancements and findings in this field, valuable insights can be gained regarding the potential and future directions of LFAs in cardiovascular diagnostics.

Automated summary

Lateral flow assays (LFAs) are widely used paper-based biosensors for rapid detection and quantification of analytes. LFAs have shown great potential as point-of-care (POC) tools, especially for time-sensitive decisions like cardiovascular events. This comprehensive review consolidates the existing scientific literature on LFAs targeting cardiovascular biomarkers, providing insights into the potential and future directions of LFAs in cardiovascular diagnostics.